• A-
  • A
  • A+

Nuria’s report on Patient Centric Clinical Trials

#efpPCCT: Patient Centric Clinical Trials (London)

Last 8th and 9th June this event was held at the Hilton Tower Hotel in London, where pharma and patients gathered to answer the following question:

“Are we running towards Patient Centric Clinical Trials?”
Several pharma companies like LEO Pharma, Pfizer, Novartis and Sanofi (to name some) talked to the audience about their experience in working with the patient instead of for the patient and creating collaboration when it comes to research and development in treatments and medicine.
Lupus Europe was there and had a chance to ask some questions and have a chat with many of the speakers and people that were in London. We hope you were able to follow us on Twitter on this event and other ones we are attending!

What could be changed in Clinical Trials?
We know it and we are working towards it. Pharma is on the move as well! As the sessions went by we learnt that the following is being looked at:
 Working with patients in the design of new clinical trials more patient-centric.
 Creation of educational programs for patients and relatives
 More patient-friendly informed consents documents.
 More feed back and information before, during and after the clinical trial is finished.  More transparency.
This latest point was talked about a lot in the conference and pharma is well aware that the relationship with patients and families must continue after the trial is finished. Patients are demanding to have not only their data but the results of the whole study they have been collaborating in.
Lupus Europe offered as a collaborator in such demands as we believe they could lead to better designed clinical trials, more patient participation and, most important, more and better treatments.

Clinical trials using 2.0 technology
Several companies raised this issue: the fact of many patients not enrolling in clinical trials because of some of the following reasons:
 Distance of place of trial from home.
 Duration of the trial.
 Frequency of visits to trial site.
Many patients already struggle to conciliate their family and work life, so when it comes to participating in a clinical trial they don’t even think about it. There is just no time.
That is the reason why pharma and tech companies are working in mobile applications, web platforms, home visiting programs and other tools that could lead to clinical trials from home. We will keep you updated on this interesting concept!!
The figures...

If you could not follow this event on Twitter, don’t miss the chance!!! All that was said can be found by clicking on this link, as well as the figures of the impact #efpPCCT had in the whole world.

Thanks to all who participated in this event and thanks a lot to the EyeForPharma Team for being so kind with us and letting us be a part of this event!

June 2015